There was no significant effect of anti-drug antibodies on the pharmacokinetics of tislelizumab-jsgr. The effect of anti-drug antibodies on pharmacodynamics, safety, or effectiveness of …

Feb 9, 2025 · Tryngolza package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

TRYNGOLZA® (olezarsen) is an FDA-approved treatment in adults with FCS as an adjunct to diet. See Safety & Full Prescribing Information.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRYNGOLZA safely and effectively. See full prescribing information …

Dec 11, 2025 · Tevimbra package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TEVIMBRA safely and effectively. See full prescribing information …

Tislelizumab is approved in the EU for the treatment of ESCC, G/GEJ and three non-small cell lung cancer (NSCLC) indications. Tislelizumab is under regulatory review for extensive-stage …

Dosage modifications for TEVIMBRA for adverse reactions that require management different from these general guidelines are summarized in Table 2. Refer to the respective Prescribing …

The data below reflect information for significant adverse drug reactions for tislelizumab as monotherapy in clinical studies. Details for the significant adverse reactions for tislelizumab …

Dec 2, 2025 · In some patients with NSCLC, Tevimbra can be given before (neoadjuvant treatment) and after (adjuvant treatment) surgery. Depending on the cancer being treated, …